Biomedical Engineering Reference
In-Depth Information
Campbell, D.J. and M. Woodward, J.P. Chalmers, S.A. Colman, A.J. Jenkins, B.E. Kemp, B.C.
Neal, A. Patel, and S.W. MacMahon. 2006. Soluble vascular cell adhesion molecule 1 and
N-terminal pro-B-type natriuretic peptide in predicting ischemic stroke in patients with
cerebrovascular disease. Arch. Neurol. 63: 60-65.
Carnes, C.A. and M.K. Chung, T. Nakayama, H. Nakayama, R.S. Baliga, S. Piao, A.
Kanderian, S. Pavia, R.L. Hamlin, P.M. McCarthy, J.A. Bauer, and D.R. Van Wagoner.
2001. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical
remodeling and decreases the incidence of postoperative atrial i brillation. Circ. Res.
89: E32-E38.
Conway, D.S. and P. Buggins, E. Hughes, and G.Y. Lip. 2004. Relationship of interleukin-6
and C-reactive protein to the prothrombotic state in chronic atrial i brillation. J. Am.
Coll. Cardiol. 43: 2075-2082.
Conway, D.S. and L.A. Pearce, B.S. Chin, R.G. Hart, and G.Y. Lip. 2002. Plasma von
Willebrandt factor and soluble p-selectin as indices of endothelial damage and platelet
activation in 1321 patients with nonvalvular atrial i brillation: relationship to stroke risk
factors. Circulation 106: 1962-1967.
Dudley, S.C., Jr. and N.E. Hoch, L.A. McCann, C. Honeycutt, L. Diamandopoulos, T.
Fukai, D.G. Harrison, S.I. Dikalov, and J. Langberg. 2005. Atrial i brillation increases
production of superoxide by the let atrium and let atrial appendage: role of the NADPH
and xanthine oxidases. Circulation 112: 1266-1273.
Gawaz, M. and F.J. Neumann, T. Dickfeld, W. Koch, K.L. Laugwitz, H. Adelsberger, K.
Langenbrink, S. Page, D. Neumeier, A. Schomig, and K. Brand. 1998. Activated platelets
induce monocyte chemotactic protein-1 secretion and surface expression of intercellular
adhesion molecule-1 on endothelial cells. Circulation 98: 1164-1171.
Go, A.S. and E.M. Hylek, K.A. Phillips, Y. Chang, L.E. Henault, J.V. Selby, and D.E. Singer.
2001. Prevalence of diagnosed atrial i brillation in adults: national implications for
rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in
Atrial Fibrillation (ATRIA) Study. JAMA 285: 2370-2375.
Goette, A. and A. Bukowska, U. Lendeckel, M. Erxleben, M. Hammwöhner, D. Strugala,
J. Pfeif enberger, F.W. Rohl, C. Huth, M.P. Ebert, H.U. Klein, and C. Rocken. 2008a.
Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule
expression. Circulation 117: 732-742.
Goette, A. and A. D'Alessandro, A. Bukowska, S. Kropf, C. Mewis, C. Stellbrink, J.
Tebbenjohanns, C. Weiss, and U. Lendeckel. 2008b. Rationale for and design of the
CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study
of the ef ect of irbesartan on oxidative stress and adhesion molecules in patients with
persistent atrial i brillation. Clin. Drug Invest. 28: 565-572.
Goette, A. and C. Honeycutt, and J.J. Langberg. 1996. Electrical remodeling in atrial
i brillation. Time course and mechanisms. Circulation 94: 2968-2974.
Goette, A. and A. Ittenson, P. Hof manns, S. Reek, W. Hartung, H. Klein, S. Ansorge, and
J.C. Geller. 2000a. Increased expression of P-selectin in patients with chronic atrial
i brillation. Pacing Clin. Electrophysiol. 23: 1872-1875.
Goette, A. and T. Staack, C. Rocken, M. Arndt, J.C. Geller, C. Huth, S. Ansorge, H.U. Klein,
and U. Lendeckel. 2000b. Increased expression of extracellular signal-regulated kinase
